Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial by Mirza, Mansoor Raza, MD, Åvall Lundqvist, Elisabeth, PhD, Birrer, Michael J, Prof, dePont Christensen, Rene, PhD, Nyvang, Gitte-Bettina, MD, Malander, Susanne, PhD, Anttila, Maarit, PhD, Werner, Theresa L, MD, Lund, Bente, MD, Lindahl, Gabriel, MD, Hietanen, Sakari, PhD, Peen, Ulla, MD, Dimoula, Maria, MD, Roed, Henrik, DMSci, Ør Knudsen, Anja, MD, Staff, Synnöve, PhD, Krog Vistisen, Anders, MD, Bjørge, Line, Prof, Mäenpää, Johanna U, Prof

Get full text